NATCO transfers Lenalidomide ANDA to Arrow

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.

This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International Limited (an affiliate of Teva Pharmaceut ical Industries Ltd) is the marketing partner of NATCO forth is product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.

Shares of Natco Pharma Ltd. was last trading in BSE at Rs. 1001.2 as compared to the previous close of Rs. 1009.85. The total number of shares traded during the day was 6287 in over 559 trades.

The stock hit an intraday high of Rs. 1019.55 and intraday low of 1001.1. The net turnover during the day was Rs. 6355142.

Source : Equity Bulls

Keywords